Difference between revisions of "MDAI"
From DMT-Nexus Wiki
(Added safety profile) |
|||
| Line 9: | Line 9: | ||
* Mental addiction | * Mental addiction | ||
| | | | ||
| − | * Cardiovascular toxicity has not been tested. As of 2013, | + | * Cardiovascular toxicity has not been tested. As of 2013, long-term studies on this substance have not been performed, so long term effects are still UNKNOWN! |
}} | }} | ||
== Brief overview - What is MDAI? == | == Brief overview - What is MDAI? == | ||
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects. Unlike similar drugs, it results in little to no stimulant effects. | 5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects. Unlike similar drugs, it results in little to no stimulant effects. | ||
Revision as of 22:17, 19 December 2013
| Safety profile |  |
|---|---|
Category:
|
|
Main effects:
|
|
Side effects:
|
|
Health risks:
|
|
Important safety remarks:
|
|
Brief overview - What is MDAI?
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects. Unlike similar drugs, it results in little to no stimulant effects.
